Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 52-Week Treatment Double-Blind, Placebo-Controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray

NCT06461949 is registered in ClinicalTrials.gov with National Institute on Deafness and Other Communication Disorders (NIDCD) as lead sponsor.

NCT NCT06461949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06461949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 52-Week Treatment Double-Blind, Placebo-Controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Phase
Phase 3
Overall status
Withdrawn
Start date
July 17, 2024
Completion date
July 17, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allergic fungal rhinosinusitis (afrs), asthma, chronic rhinosinusitis (crs), nasal polyps